Assessment of bone marrow angiogenesis in patients with acute myeloid leukemia by using contrast-enhanced MR imaging with clinically approved iron oxides: initial experience.

PURPOSE To prospectively assess bone marrow (BM) angiogenesis in patients with acute myeloid leukemia (AML) by using iron oxide-enhanced magnetic resonance (MR) imaging. MATERIALS AND METHODS The study was institutional ethics committee approved. Informed signed consent was obtained from each study participant. The requirement for informed consent for use of data from a reference database was waived. Eleven patients (seven women, four men; mean age, 53 years+/-4.40 [standard deviation]) with an initial diagnosis of AML were enrolled in the study and underwent T2*-weighted two-echo echo-planar MR imaging of the pelvis before and after intravenous injection of a clinically approved iron oxide blood-pool contrast agent. Six healthy control subjects (one woman, five men; mean age, 35 years+/-2.31) were examined with the same MR protocol. The iron oxide-induced change in R2* relaxation rate (DeltaR2*) was calculated, and the vascular volume fraction (VVF) of the BM was derived by dividing the DeltaR2* of the BM by the DeltaR2* of the muscle. Parametric DeltaR2* maps were calculated to visualize vessel distribution. Patients underwent BM biopsy for correlative determination of microvessel density (MVD) and vascular endothelial growth factor (VEGF). Differences in DeltaR2*, VVF, VEGF, and MVD were compared by using the Wilcoxon rank sum test. RESULTS DeltaR2* maps showed prominent areas of highly vascularized BM in the patients with AML, whereas the control subjects had moderately vascularized BM with homogeneous vessel distribution. Quantitative analysis revealed VVF values to be significantly higher in patients with AML than in control subjects: The mean VVF in the pelvis was 9.18%+/-1.54 for patients versus 3.91%+/-0.61 for control subjects (P=.010). In accordance with MR results, MVD (P=.009) and VEGF expression (P=.017) were significantly elevated in the AML group compared with values in the control group. CONCLUSION Iron oxide-enhanced MR imaging enables assessment of BM angiogenesis in patients with AML.

[1]  W. Heindel,et al.  First‐pass and equilibrium‐MRA of the aortoiliac region with a superparamagnetic iron oxide blood pool MR contrast agent (SH U 555 C): results of a human pilot study , 2004, NMR in biomedicine.

[2]  A. Chott,et al.  Bone Marrow Microvessel Density and it's Prognostic Significance in AML , 2004, Leukemia & lymphoma.

[3]  M. Beksac,et al.  Bone Marrow Microvessel Density (MVD) in Adult Acute Myeloid Leukemia (AML): Therapy Induced Changes and Effects on Survival , 2004, Leukemia & lymphoma.

[4]  A. Harris,et al.  Microvessel density, endothelial-cell proliferation and carbonic anhydrase IX expression in haematological malignancies, bone-marrow metastases and monoclonal gammopathy of undetermined significance , 2004, Virchows Archiv.

[5]  P. Gaulard,et al.  Bone marrow with diffuse tumor infiltration in patients with lymphoproliferative diseases: dynamic gadolinium-enhanced MR imaging. , 2003, Radiology.

[6]  A. Rahmouni,et al.  Normal spinal bone marrow in adults: dynamic gadolinium-enhanced MR imaging. , 2003, Radiology.

[7]  H. Serve,et al.  Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia , 2002, Leukemia.

[8]  C. Bremer,et al.  Contrast-enhanced blood-pool MR angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits. , 2002, Radiology.

[9]  E. Rummeny,et al.  Iron-oxide-enhanced MR imaging of bone marrow in patients with non-Hodgkin's lymphoma: differentiation between tumor infiltration and hypercellular bone marrow , 2002, European Radiology.

[10]  T. Kessler,et al.  Angiogenese bei hämatologischen Neoplasien , 2001, Oncology Research and Treatment.

[11]  W. Berdel,et al.  Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. , 2001, Blood.

[12]  D M Shames,et al.  MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. , 2001, Radiology.

[13]  A. Yuan,et al.  Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non‐small‐cell lung cancer , 2000, International journal of cancer.

[14]  E. Estey,et al.  Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. , 2000, Blood.

[15]  R. Brasch,et al.  MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. , 2000, European journal of radiology.

[16]  W. Berdel,et al.  Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. , 2000, Blood.

[17]  W. Berdel,et al.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. , 2000, Blood.

[18]  R Weissleder,et al.  Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin. , 2000, European journal of cancer.

[19]  W. Dupont,et al.  Transforming Growth Factor-β and Breast Cancer Risk in Women With Mammary Epithelial Hyperplasia. , 1999, Journal of the National Cancer Institute.

[20]  R. Weissleder,et al.  In vivo assessment of vascular endothelial growth factor‐induced angiogenesis , 1999, International journal of cancer.

[21]  E. Brambilla,et al.  Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF‐R1‐Flt1 and VEGF‐R2‐Flk1/KDR) in non‐small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival , 1999, The Journal of pathology.

[22]  B R Rosen,et al.  NMR imaging of changes in vascular morphology due to tumor angiogenesis , 1998, Magnetic resonance in medicine.

[23]  H. Hawighorst,et al.  Erfassung angiogeneseabhängiger Parameter mittels funktioneller MRT : Korrelation mit der Histomorphologie sowie Abklärung der klinischen Relevanz als Prognosefaktor am Beispiel des Zervixkarzinomes , 1998 .

[24]  G Brix,et al.  Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. , 1998, Cancer research.

[25]  P J Drew,et al.  Microvessel density in invasive breast cancer assessed by dynamic gd‐dtpa enhanced MRI , 1997 .

[26]  D M Shames,et al.  Comparison of albumin‐(Gd‐DTPA)30 and Gd‐DTPA‐24‐cascade‐polymer for measurements of normal and abnormal microvascular permeability , 1997, Journal of magnetic resonance imaging : JMRI.

[27]  D M Shames,et al.  A MRI spatial mapping technique for microvascular permeability and tissue blood volume based on macromolecular contrast agent distribution , 1997, Magnetic resonance in medicine.

[28]  L D Buadu,et al.  Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. , 1996, Radiology.

[29]  R. Jain,et al.  Physiologically based kinetic model of effector cell biodistribution in mammals: implications for adoptive immunotherapy. , 1996, Cancer research.

[30]  R. Paola,et al.  Correlation Between Contrast Enhancement in Dynamic Magnetic Resonance Imaging of the Breast and Tumor Angiogenesis , 1994, Investigative radiology.

[31]  J. Folkman.  Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. , 1990, Cancer metastasis reviews.

[32]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[33]  J. Folkman,et al.  Tumor Behavior in Isolated Perfused Organs: In Vitro Growth and Metastases of Biopsy Material in Rabbit Thyroid and Canine Intestinal Segment , 1966, Annals of surgery.

[34]  Vasilis Ntziachristos,et al.  Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. , 2003, Radiology.

[35]  N. Kay,et al.  Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia , 2000, Leukemia.

[36]  M. Knopp,et al.  Angiogenesis of cancer of the cervix. Contrast-enhanced dynamic MRT, histological quantification of capillary density and lymph system infiltration , 1998, Der Radiologe.

[37]  N. van Bruggen,et al.  Assessing tumor angiogenesis using macromolecular MR imaging contrast media , 1997, Journal of magnetic resonance imaging : JMRI.

[38]  W T Yuh,et al.  Assessment of tumor microcirculation: A new role of dynamic contrast MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.